Abstract
Background The role of DNA methylation (DNAm) in the carcinogenesis of colorectal cancer (CRC) diagnosed <50years of age (early-onset CRC or EOCRC) is currently unknown. We investigated aberrant DNAm changes and the contribution of ageing-associated methylomic drift, and age acceleration to EOCRC carcinogenesis.
Methods Genome-wide DNAm profiling using the Infinium HM450K on 97 EOCRC tumour and 54 normal colonic mucosa samples was compared with: 1) intermediate-onset CRC (IOCRC; diagnosed between 50-70 years; 343 tumour and 35 normal); and 2) late-onset CRC (LOCRC; >70 years; 318 tumour and 40 normal). CpGs associated with age-related methylation drift were identified using a public dataset of 231 normal mucosa samples from people without CRC. DNAm-age was estimated using epiTOC2.
Results Common to all three age-of-onset groups, 88,385 (20% of all CpGs) CpGs were differentially methylated between tumour and normal mucosa. We identified 234 differentially methylated genes that were unique to the EOCRC group. In normal mucosa from people without CRC, we identified 28,154 CpGs that undergo ageing-related DNAm drift and of those, 65% were aberrantly methylated in EOCRC tumours. Based on the mitotic-based DNAm clock epiTOC2, we identified age acceleration in normal mucosa of people with EOCRC compared with normal mucosa from the IOCRC, LOCRC groups (p=3.7×10−16) and young people without CRC (p=5.8×10−6).
Conclusion EOCRC acquires unique DNAm alterations at 234 loci. CpGs associated with ageing-associated drift were widely affected in EOCRC without needing the decades-long accrual of DNAm drift as commonly seen in intermediate- and late-onset CRCs. We found accelerated ageing in normal mucosa from people with EOCRC, as evidenced by a faster stem-cell division rate, potentially contributing to EOCRC carcinogenesis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414 and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database (ACD). New South Wales (NSW) cancer registry data were obtained via the ACD with the assistance of the NSW Ministry of Health. The Colon Cancer Family Registry (CCFR)was supported by the National Cancer Institute of the National Institutes of Health under Award Number U01CA167551 and through a cooperative agreement with the Australasian Colorectal Cancer Family Registry (NCI/NIH U01 CA074778 and U01/U24 CA097735) and by the Victorian Cancer Registry, Australia. This research was performed under CCFR approved project C-AU-0312-01. DDB is supported by a NHMRC R.D. Wright Career Development Fellowship, a NHMRC Emerging Leadership Investigator grant and by funding from the University of Melbourne Research at Melbourne Accelerator Program (R@MAP). PG is supported by an Australian Government Research Training Program Scholarship. AKW is a NHMRC Career Development Fellow. JLH is a NHMRC Senior Principal Research Fellow. MAJ is a NHMRC Senior Research Fellow.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Cancer Council of Victoria and University of Melbourne Human Research Ethics Committees.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets of the current study are available from the corresponding author on reasonable request.
ABBREVIATIONS
- AA
- Age acceleration
- ACCFR
- Australian Colon Cancer Family Registry
- AgeDx
- Age of diagnosis
- CIMP
- CpG Island Methylator Phenotype
- CpG
- Cytosine-(phosphate)-Guanine dinucleotide
- CRC
- Colorectal cancer
- DNAm
- DNA methylation
- DMP
- Differentially methylated probe
- DMR
- Differentially methylated region
- Dx
- diagnosis
- EOCRC
- Early-onset colorectal cancer
- IOCRC
- Intermediate-onset colorectal cancer
- LOCRC
- Late-onset colorectal cancer
- FDR
- False discovery rate
- MMR
- Mismatch repair
- MSI
- Microsatellite instable
- MSS
- Microsatellite stable
- MCCS
- Melbourne Collaborative Cohort Study
- NM
- Normal colonic mucosa
- KEGG
- Kyoto Encyclopedia of Genes and Genomes
